Literature DB >> 27034265

Clinical significance of circulating miRNA detection in lung cancer.

Chen Zhao1,2, Funian Lu1, Hongxia Chen1, Fuqiang Zhao1, Ziwen Zhu1,2, Xianda Zhao1, Honglei Chen3.   

Abstract

Lung cancer is the most common cancer in the world and the leading cause of tumor death among males. MicroRNAs (miRNAs) are single-stranded RNAs of approximately 22 nucleotides and constituted a new class of gene regulators in humans. As a novel class of emerging biomarkers, the aberrant expression of miRNA has been detected in various tumors. miRNAs are secreted into circulation by microvesicles from the broken tumor cells and act as either oncogenes or tumor suppressors in tumor tissues. In this review, we summarized different circulating miRNAs and their expression level as well as predictable values in lung cancer patients which were investigated in recent 5 years. Circulating miRNAs are found to be dysregulated and have association with clinicopathological parameters and overall survival in lung cancer patients. In conclusion, circulating miRNAs have the potential for distinguishing lung cancer patients from healthy individuals, with the advantages of stabilities, noninvasiveness and cost-effectiveness.

Entities:  

Keywords:  Circulating microRNAs; Diagnosis; Lung cancer; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27034265     DOI: 10.1007/s12032-016-0757-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  42 in total

1.  Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers.

Authors:  Qiang Zhao; Jun Cao; Yi-Chen Wu; Xiang Liu; Jing Han; Xian-Cong Huang; Lie-Hao Jiang; Xiu-Xiu Hou; Wei-Min Mao; Zhi-Qiang Ling
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer.

Authors:  Niels H H Heegaard; Aaron J Schetter; Judith A Welsh; Mitsuhiro Yoneda; Elise D Bowman; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

3.  Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.

Authors:  Carina Roth; Sabine Kasimir-Bauer; Klaus Pantel; Heidi Schwarzenbach
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

4.  Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.

Authors:  Fermín Mar-Aguilar; Jorge A Mendoza-Ramírez; Ismael Malagón-Santiago; Perla K Espino-Silva; Sandra K Santuario-Facio; Pablo Ruiz-Flores; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

5.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

6.  Circulating microRNAs as specific biomarkers for breast cancer detection.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Hong Chuan Jin; Candy P H Leung; Edmond S K Ma; Roberta Pang; Daniel Chua; Kent-Man Chu; W L Law; Simon Y K Law; Ronnie T P Poon; Ava Kwong
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

7.  Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer.

Authors:  T Kawaguchi; S Komatsu; D Ichikawa; R Morimura; M Tsujiura; H Konishi; H Takeshita; H Nagata; T Arita; S Hirajima; A Shiozaki; H Ikoma; K Okamoto; T Ochiai; H Taniguchi; E Otsuji
Journal:  Br J Cancer       Date:  2013-01-17       Impact factor: 7.640

8.  Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma.

Authors:  Vasily N Aushev; Irina B Zborovskaya; Konstantin K Laktionov; Nicolas Girard; Marie-Pierre Cros; Zdenko Herceg; Vladimir Krutovskikh
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

9.  Expression and significance of circulating microRNA-31 in lung cancer patients.

Authors:  Hai-Jun Yan; Ji-Yong Ma; Li Wang; Wei Gu
Journal:  Med Sci Monit       Date:  2015-03-09

Review 10.  miRNAs as non-invasive biomarkers for lung cancer diagnosis.

Authors:  Paola Ulivi; Wainer Zoli
Journal:  Molecules       Date:  2014-06-17       Impact factor: 4.411

View more
  11 in total

1.  miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.

Authors:  Dongmei Yang; Qiumei Zhang
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

2.  Function and mechanism of microRNA-210 in acute cerebral infarction.

Authors:  Jun Wang; Yuezhan Zhang; Feng Xu
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

3.  MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7.

Authors:  Lichun Han; Wei Wang; Wei Ding; Lijian Zhang
Journal:  J Cell Mol Med       Date:  2017-03-07       Impact factor: 5.310

Review 4.  Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.

Authors:  Kentaro Inamura
Journal:  Cells       Date:  2017-05-09       Impact factor: 6.600

Review 5.  The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis.

Authors:  Huqin Yang; Huijuan Wang; Chao Zhang; Zhaohui Tong
Journal:  Oncotarget       Date:  2016-09-27

6.  Serum MiR-4687-3p Has Potential for Diagnosis and Carcinogenesis in Non-small Cell Lung Cancer.

Authors:  Man Liu; Qiufang Si; Songyun Ouyang; Zhigang Zhou; Meng Wang; Chunling Zhao; Ting Yang; Yulin Wang; Xue Zhang; Wenbo Xie; Liping Dai; Jitian Li
Journal:  Front Genet       Date:  2020-11-23       Impact factor: 4.599

Review 7.  Circulating microRNA biomarkers for lung cancer detection in Western populations.

Authors:  Haixin Yu; Zhong Guan; Katarina Cuk; Hermann Brenner; Yan Zhang
Journal:  Cancer Med       Date:  2018-09-27       Impact factor: 4.452

8.  A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer.

Authors:  Zu-Cheng Xie; Rui-Xue Tang; Xiang Gao; Qiong-Ni Xie; Jia-Ying Lin; Gang Chen; Zu-Yun Li
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

9.  MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway.

Authors:  Liwei Ruan; Xiaojun Qian
Journal:  Biosci Rep       Date:  2019-08-23       Impact factor: 3.976

10.  MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip.

Authors:  Li Gao; Shi-Bai Yan; Jie Yang; Jin-Liang Kong; Ke Shi; Fu-Chao Ma; Lin-Zhen Huang; Jie Luo; Shu-Ya Yin; Rong-Quan He; Xiao-Hua Hu; Gang Chen
Journal:  BMC Med Genomics       Date:  2020-01-06       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.